Related Experiment Video
Updated: Dec 7, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers
Katerina Benkova1, Jana Mihalyova1, Roman Hajek1
1Department of Hematooncology, University Hospital Ostrava, 17. listopadu 1790/5, Ostrava 708 52, Czech Republic; Faculty of Medicine, University of Ostrava, Ostrava 703 00, Czech Republic.
Abstract:
Exportin 1 (XPO1), also known as chromosome maintenance 1 protein (CRM1), is the main transporter for hundreds of proteins like tumor suppressors, growth regulatory factors, oncoprotein mRNAs and others. Its upregulation leads to the inactivation of the tumor suppressor anti-neoplastic function in many cancers and logically is associated with poor prognosis. Selective inhibitors of nuclear export (SINE) are a new generation of XPO1 inhibitors that are being investigated as a promising targeted anti-cancer therapy. Selinexor is the first generation of SINE compounds that is being evaluated in many clinical trials involving solid tumors and hematological malignancies with its two approved indications for relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma. Here, we comprehensively review the current knowledge of selinexor and next generations of the SINE compounds in lymphoid and myeloid malignancies.
Insights
Exportin 1 (XPO1) inhibitors, like selinexor, show promise in treating cancers by restoring tumor suppressor function. This review covers selinexor and newer SINE compounds for lymphoid and myeloid malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Exportin 1 (XPO1) is crucial for transporting tumor suppressors and oncoproteins.
- XPO1 upregulation is linked to cancer progression and poor prognosis.
- Selective inhibitors of nuclear export (SINE) offer a targeted cancer therapy approach.
Purpose of the Study:
- To review the knowledge of selinexor and next-generation SINE compounds.
- To discuss their application in lymphoid and myeloid malignancies.
Main Methods:
- Comprehensive literature review of XPO1 inhibitors.
- Analysis of clinical trial data for selinexor.
- Evaluation of SINE compounds in hematological malignancies.
Main Results:
- Selinexor is the first-in-class SINE compound, approved for multiple myeloma and diffuse large B-cell lymphoma.
- SINE compounds demonstrate targeted anti-cancer activity.
- Ongoing research explores next-generation SINEs for broader applications.
Conclusions:
- Selinexor and other SINEs represent a significant advancement in cancer therapy.
- Further investigation into SINE compounds is warranted for lymphoid and myeloid malignancies.
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Nuclear Protein Sorting
Proteins targeted to the nucleus carry nuclear localization signals or NLS recognized by import receptors in the cytosol. Similarly, proteins with nuclear export signals are recognized by export receptors. Import and export receptors are...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Nuclear Localization Signals and Import
Nuclear Export of mRNA
Nuclear Export of mRNA

